Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group

被引：25

作者：

Mendoza, Nicolas ^{[1
]}

Ramirez, Isabel ^{[1
]}

de la Viuda, Esther ^{[1
]}

Coronado, Pluvio ^{[1
]}

Baquedano, Laura ^{[1
]}

Llaneza, Placido ^{[1
]}

Nieto, Veronica ^{[1
]}

Otero, Borja ^{[1
]}

Sanchez-Mendez, Sonia ^{[1
]}

Alvarez de Frutos, Visitacion ^{[2
]}

Andraca, Leire ^{[3
]}

Barriga, Patricio ^{[4
]}

Benitez, Zully ^{[5
]}

Bombas, Teresa ^{[4
]}

Jesus Cancelo, Ma ^{[6
]}

Cano, Antonio ^{[7
]}

Castelo Branco, Camil ^{[8
]}

Correa, Marta ^{[9
]}

Luis Doval, Jose ^{[1
]}

Fasero, Maria ^{[1
]}

Fiol, Gabriel ^{[1
]}

Garello, Nestor C. ^{[10
]}

Genazzani, Andrea R. ^{[8
]}

Isabel Gomez, Ana ^{[11
]}

Angeles Gomez, Ma ^{[1
]}

Gonzalez, Silvia ^{[1
]}

Goulis, Dimitrios G. ^{[7
]}

Guinot, Misericordia ^{[1
]}

Rolando Hernandez, Luis ^{[10
]}

Herrero, Sonia ^{[12
]}

Iglesias, Eva ^{[1
]}

Rosa Jurado, Ana ^{[13
]}

Lete, Inaki ^{[1
]}

Lubian, Daniel ^{[1
]}

Martinez, Milagros ^{[1
]}

Nieto, Anibal ^{[1
]}

Nieto, Laura ^{[1
]}

Palacios, Santiago ^{[14
]}

Pedreira, Milagros ^{[15
]}

Perez-Campos, Ezequiel ^{[1
]}

Pla, Maria Jesus ^{[16
]}

Presa, Jesus ^{[1
]}

Quereda, Francisco ^{[1
]}

Ribes, Miriam ^{[1
]}

Romero, Pablo ^{[1
]}

Roca, Beatriz ^{[1
]}

Sanchez-Capilla, Antonio ^{[17
]}

Sanchez-Borrego, Rafael ^{[18
]}

Santaballa, Ana ^{[19
]}

Santamaria, Amparo ^{[20
]}

机构：

[1] Assoc Espanola Estudio Menopausia AEEM, Madrid, Spain

[2] Soc Espanola Endocrinol & Nutr SEEN, Madrid, Spain

[3] Soc Espanola Farm Comunitaria SEFAC, Madrid, Spain

[4] Red Iberoamer Salud Sexual & Reprod REDISSER, Madrid, Spain

[5] Federac Latino Amer Soc Climaterio & Menopausia F, Madrid, Spain

[6] Soc Espanola Ginecol & Obstet SEGO, Madrid, Spain

[7] European Menopause & Andropause Soc EMAS, Madrid, Spain

[8] European Soc Gynecol ESG, Madrid, Spain

[9] Soc Espanola Contracepc SEC, Madrid, Spain

[10] Federac Latino Amer Soc Obstet & Ginecol FLASOG, Madrid, Spain

[11] Soc Espanola Senol & Patol Mamaria SESPM, Madrid, Spain

[12] Soc Espanola Trombosis & Hemostasia SETH, Madrid, Spain

[13] Soc Espanola Med Atenc Primaria SEMERGEN, Madrid, Spain

[14] Int Menopause Soc IMS, Madrid, Spain

[15] Soc Espanola Cardiol SEC, Madrid, Spain

[16] Secc Ginecol Oncol SEGO, Madrid, Spain

[17] Soc Espanola Patol Digest SEPD, Madrid, Spain

[18] Fdn Espanola Estudio Menopausia FEEM, Madrid, Spain

[19] Soc Espanola Oncol Med SEOM, Madrid, Spain

[20] Soc Espanola Hernatol & Hemoterapia SEHH, Madrid, Spain

[21] Int Soc Gynecol Endocrinol ISGE, Madrid, Spain

[22] Soc Espanola Obesidad SEED, Madrid, Spain

来源：

MATURITAS | 2022年 / 166卷

关键词：

Menopausal hormone therapy; Menopause; Eligibility criteria; Medical conditions; ESTROGEN-REPLACEMENT THERAPY; ORAL-CONTRACEPTIVE STEROIDS; ACUTE MYOCARDIAL-INFARCTION; HEALTHY POSTMENOPAUSAL WOMEN; AMBULATORY BLOOD-PRESSURE; CONTINUOUS COMBINED HRT; CARDIOVASCULAR RISK-FACTORS; CONJUGATED EQUINE ESTROGEN; PLACEBO-CONTROLLED TRIAL; BREAST-CANCER SURVIVORS;

D O I：

10.1016/j.maturitas.2022.08.008

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

This project aims to develop eligibility criteria for menopausal hormone therapy (MHT). The tool should be similar to those already established for contraception A consortium of scientific societies coordinated by the Spanish Menopause Society met to formulate recommendations for the use of MHT by women with medical conditions based on the best available evidence. The project was developed in two phases. As a first step, we conducted 14 systematic reviews and 32 metanalyses on the safety of MHT (in nine areas: age, time of menopause onset, treatment duration, women with thrombotic risk, women with a personal history of cardiovascular disease, women with metabolic syndrome, women with gastrointestinal diseases, survivors of breast cancer or of other cancers, and women who smoke) and on the most relevant pharmacological interactions with MHT. These systematic reviews and metanalyses helped inform a structured process in which a panel of experts defined the eligibility criteria according to a specific framework, which facilitated the discussion and development process. To unify the proposal, the following eligibility criteria have been defined in accordance with the WHO international nomenclature for the different alternatives for MHT (category 1, no restriction on the use of MHT; category 2, the benefits outweigh the risks; category 3, the risks generally outweigh the benefits; category 4, MHT should not be used). Quality was classified as high, moderate, low or very low, based on several factors (including risk of bias, inaccuracy, inconsistency, lack of directionality and publication bias). When no direct evidence was identified, but plausibility, clinical experience or indirect evidence were available, "Expert opinion" was categorized. For the first time, a set of eligibility criteria, based on clinical evidence and developed according to the most rigorous methodological tools, has been defined. This will provide health professionals with a powerful decision-making tool that can be used to manage menopausal symptoms.

引用

页码：65 / 85

页数：21

共 251 条

[1] IMPAIRMENT OF CAFFEINE CLEARANCE BY CHRONIC USE OF LOW-DOSE ESTROGEN-CONTAINING ORAL-CONTRACEPTIVES [J].

ABERNETHY, DR ;

TODD, EL .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (04) :425-428

[2] IMPAIRMENT OF DIAZEPAM METABOLISM BY LOW-DOSE ESTROGEN-CONTAINING ORAL-CONTRACEPTIVE STEROIDS [J].

ABERNETHY, DR ;

GREENBLATT, DJ ;

DIVOLL, M ;

ARENDT, R ;

OCHS, HR ;

SHADER, RI .

NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (13) :791-792

[3] IMIPRAMINE DISPOSITION IN USERS OF ORAL-CONTRACEPTIVE STEROIDS [J].

ABERNETHY, DR ;

GREENBLATT, DJ ;

SHADER, RI .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (06) :792-797

[4] Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up [J].

Alexander, KP ;

Newby, LK ;

Hellkamp, AS ;

Harrington, RA ;

Peterson, ED ;

Kopecky, S ;

Langer, A ;

O'Gara, P ;

O'Connor, CM ;

Daly, RN ;

Califf, RM ;

Khan, S ;

Fuster, V .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (01) :1-7

[5] GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction [J].

Alonso-Coello, Pablo ;

Schunemann, Holger J. ;

Moberg, Jenny ;

Brignardello-Petersen, Romina ;

Akl, Elie A. ;

Davoli, Marina ;

Treweek, Shaun ;

Mustafa, Reem A. ;

Rada, Gabriel ;

Rosenbaum, Sarah ;

Morelli, Angela ;

Guyatt, Gordon H. ;

Oxman, Andrew D. .

BMJ-BRITISH MEDICAL JOURNAL, 2016, 353

[6]

ALTSCHULER SL, 1974, OBSTET GYNECOL, V44, P771

[7] Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial [J].

Anderson, Garnet L. ;

Chlebowski, Rowan T. ;

Aragaki, Aaron K. ;

Kuller, Lewis H. ;

Manson, JoAnn E. ;

Gass, Margery ;

Bluhm, Elizabeth ;

Connelly, Stephanie ;

Hubbell, F. Allan ;

Lane, Dorothy ;

Martin, Lisa ;

Ockene, Judith ;

Rohan, Thomas ;

Schenken, Robert ;

Wactawski-Wende, Jean .

LANCET ONCOLOGY, 2012, 13 (05) :476-486

[8] Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus [J].

Andersson, B ;

Mattsson, LA ;

Hahn, L ;

Marin, P ;

Lapidus, L ;

Holm, G ;

Bengtsson, BA ;

Bjorntorp, P .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :638-643

[9] Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects [J].

Andrews, Emma ;

Damle, Bharat D. ;

Fang, Annie ;

Foster, Grover ;

Crownover, Penelope ;

LaBadie, Robert ;

Glue, Paul .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (04) :531-539

[10] Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women [J].

Angeja, BG ;

Shlipak, MG ;

Go, AS ;

Johnston, SC ;

Frederick, PD ;

Canto, JG ;

Barron, HV ;

Grady, D .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (05) :1297-1301

← 1 2 3 4 5 6 7 8 9 10 →